Project 2025 Tracker
Checked

Reverse mifepristone approval or restore in-person dispensing

Not implementedLitigation pending

FDA is reviewing the drug; telehealth and mail access continue after the Supreme Court blocked a lower-court order in May 2026.

Last changed Last checked
Report an error

What the proposal says

  • The HHS chapter recommends reversing FDA's approval of mifepristone, or at minimum restoring in-person dispensing and earlier gestational limits and stopping mail-order distribution.[1]
Chapter 14: Department of Health and Human Services
By Roger Severino
Printed pages 458–459 · open PDF at page 490 (est.)

What has happened

  • FDA announced a comprehensive review of mifepristone, including its 2023 dispensing rules, in September 2025.[2]
  • On May 1, 2026, a Fifth Circuit panel reinstated in-person dispensing nationwide in Louisiana v. FDA; on May 14, 2026, the Supreme Court blocked that order while litigation continues.[2]

What is in effect now

  • Mifepristone can still be prescribed by telehealth and dispensed by mail or retail pharmacy.[2]

What remains incomplete

  • AnalysisFDA has not changed the drug's approval or dispensing requirements as of the verification date.

Why it matters

  • AnalysisMedication abortion is the most common method in the U.S.; restoring in-person dispensing would end telehealth access nationwide.

Uncertainty and disputed points

  • AttributedReporting indicates FDA told a court its safety review should finish by March 2027; this date has not been confirmed from the court filing.[2]

Status history

DateStatusNote
May 14, 2026Not implementedFDA review ongoing; Supreme Court preserves current rules. (Litigation pending)

Not implemented: No operative action toward the objective has been found. Announcements and drafts alone do not count. Definitions

Sources

  1. [1]Mandate for Leadership: The Conservative Promise (Project 2025), full text The Heritage Foundation, 2023. Accessed Nov. 17, 2026. Archived copyPrinted page numbers are cited throughout. The project2025.org domain now redirects; this Heritage-hosted copy and the Internet Archive copy are retained.
  2. [2]Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court KFF, May 14, 2026. Accessed Nov. 17, 2026.